Market Signal Briefing

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Wealthfront To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Wealthfront stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - February 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Wealthfront Corporation ("Wealthfront" or the "Company") (NASDAQ: WLTH).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Shares of Wealthfront Corporation declined sharply following the company's first post-IPO earnings release, pressured by disappointing asset flow figures and emerging investor concerns about strategic exposures underpinning its mortgage business. The stock sell-off came as Wealthfront reported softer net inflows in recent months, signaling a slowdown in client acquisitions and cash management balances relative to prior periods. Additionally, heightened market scrutiny over the CEO's ownership stake in a banking partner central to the firm's mortgage initiative has added to investor uncertainty, fueling speculation around potential conflicts of interest and long-term integration risks.

Since the company's IPO on or around December 12, 2025, at $14.00 per share, the stock has fallen $3.74, or 26.71%, to close at $10.26 on January 14, 2026.

To learn more about the Wealthfront investigation, go to www.faruqilaw.com/WLTH or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284721

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Helen of Troy To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Helen of Troy stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - February 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helen of Troy Limited ("Helen of Troy" or the "Company") (NASDAQ: HELE).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On October 9, 2025, Helen of Troy reported financial results for the second quarter of fiscal 2026, revealing an approximately 8.9% year-over-year decline in consolidated net sales to roughly $431.8 million. The Company also reported a GAAP diluted loss per share of $13.44, driven in part by significant charges, and adjusted diluted earnings per share of approximately $0.59, down substantially from $1.21 in the prior-year period.

Following this news, Helen of Troy's common stock declined sharply. The Company's shares fell $6.90 per share, or approximately 25.0%, to close at $20.71 per share on October 9, 2025.

To learn more about the Helen of Troy investigation, go to www.faruqilaw.com/HELE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284719

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - February 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. ("Picard" or the "Company") (NYSE American: PMI) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Picard was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) that Picard's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price.

On October 24, 2025, Picard Medical, Inc. (NYSE: PMI) shares closed at $5.31, a steep decline from the prior trading session's close of $13.20 on October 23, 2025. This represents a drop of $7.89 per share, or approximately a 59.8% decrease in value in a single session, marking one of the most significant one-day declines since the company's recent IPO.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Picard Medical's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Picard Medical class action, go to www.faruqilaw.com/PMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284727

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Perion Networks' FY '26 guidance implies 11% contribution ex-TAC growth at the midpoint, with adjusted EBITDA margins expanding 100 bps to 23%. Management targets greater than 20% CAGR in contribution ex-TAC through 2028, alongside margin expansion to 28%. Net cash of $285M equals more than 80% of the current market cap.

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients 

78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement)

, /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 company-sponsored abstracts being presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference.

At Week 140, 80.8% of patients taking TREMFYA® were in clinical remissiona. Additionally, 78.6% of patients achieved histo-endoscopic mucosal improvement (HEMI)b, and 53.6% of patients were in endoscopic remissionc, respectively.d  Approximately 89% of eligible study participants combined completed treatment through Week 140. Nearly all participants who achieved clinical remission at Week 140 were corticosteroid-free for at least eight weeks.1

The study also showed that of those in clinical remission at Week 44, 87.5% maintained clinical remission through Week 140. Efficacy was sustained regardless of prior biologic and/or JAK inhibitor treatment history, and no new safety concerns were observed.1

"Ulcerative colitis is a lifelong condition that can significantly impact patients' overall health and they need treatment options that remain effective and well-tolerated over time," said Laurent Peyrin-Biroulet, MD, PhD, study investigator.e "The QUASAR long-term study shows the sustained ability of TREMFYA to deliver durable results, with consistent outcomes regardless of previous biologic or JAK inhibitor treatment. With high study retention and no new safety concerns over this extended time period, the data strengthen confidence in the long-term use of TREMFYA in ulcerative colitis." 

"These findings highlight the endoscopic outcomes that can be achieved with TREMFYA, raising expectations for what is possible for patients with ulcerative colitis," said Esi Lamousé-Smith, MD, PhD, Vice President, Gastroenterology Disease Area Lead, Immunology, Johnson & Johnson. "Patients who achieve endoscopic remission experience fewer flare-ups and are less likely to need steroids or require surgery over time. We are energized by these findings and remain focused on delivering treatments that help more patients achieve meaningful, lasting disease control."

TREMFYA® is the first and only approved, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases. Findings are based on in vitro studies. 2 3 4 5 6 

TREMFYA® has received U.S. Food and Drug Administration (FDA) and European Commission (EC) approval for both SC and IV induction options for the treatment of adults with moderately to severely active Crohn's disease and U.S. FDA approval for both SC and IV induction options for the treatment of adults with moderately to severely active ulcerative colitis. TREMFYA® is approved by the EC for the treatment of adult patients with moderately to severely active ulcerative colitis and is currently administered via an IV induction regimen, followed by a SC maintenance regimen.

Two other Johnson & Johnson-sponsored abstracts were selected as Top 10 oral abstracts by ECCO, highlighting continued commitment to providing treatment options to those with inflammatory bowel disease:

Results from the Phase 2b ANTHEM-UC study of icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, demonstrating its impact on systemic and tissue biomarkers of inflammatory burden in UC.7   Primary safety results from the UNITI Jr study of STELARA® (ustekinumab) showing that it was effective and well-tolerated, with no new safety signals, in treating pediatric patients with Crohn's disease.8 For a full list of all Johnson & Johnson data being presented at ECCO visit: https://www.jnj.com/innovativemedicine/immunology/gastroenterology.  

Editor's Notes: 

a. Clinical remission was defined as a Mayo stool frequency subscore of 0 or 1 and not increased from induction baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopic subscore (MES) of 0 or 1.
b. Histo-endoscopic mucosal improvement was defined as a combination of endoscopic improvement and histologic improvement (neutrophil infiltration in <5% of crypts, no crypts destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. 
c. Endoscopic remission (normalization) was defined as a MES of 0.
d. As observed. Data were analyzed using 2 methods: 'nonresponder imputation' (NRI) accounting for patients with treatment failure or missing data, and 'as observed'. NRI results were consistent with as observed.
e. Dr. Laurent Peyrin-Biroulet is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.

About the QUASAR Program (NCT04033445)
QUASAR is a randomized, double-blind, placebo-controlled, parallel group, multicenter, Phase 2b/3 program designed to evaluate the efficacy and safety of TREMFYA® in adults with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g., thiopurines or corticosteroids), prior biologics (TNF antagonists or vedolizumab) and/or JAK inhibitors (tofacitinib). QUASAR included a Phase 2b dose-ranging induction study, a confirmatory Phase 3 induction study, and a Phase 3 randomized withdrawal maintenance study. In the Phase 3 induction study, patients received either TREMFYA® 200 mg or placebo by IV infusion at Weeks 0, 4, and 8. In the Phase 3 maintenance study, patients received a SC maintenance regimen of either TREMFYA® 200 mg q4w, TREMFYA® 100 mg q8w, or placebo. The ongoing long-term extension study provides an additional 4 years of treatment. Efficacy, safety, pharmacokinetics, immunogenicity, and biomarkers are assessed at specified time points.9 

About ANTHEM-UC (NCT06049017)
ANTHEM-UC is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g., thiopurines or corticosteroids), prior biologics (TNF antagonists or vedolizumab) and/or ozanimod or approved JAK inhibitors. The study is evaluating three once-daily dosages of icotrokinra taken orally. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.10

About UNITI JR (NCT04673357)
UNITI-Jr is a randomized, double-blind Phase 3 study evaluating the efficacy, safety, and pharmacokinetics of ustekinumab in 48 pediatric patients (aged 2-17) with moderately to severely active Crohn's disease (defined by a Pediatric Crohn's Disease Activity Index [PCDAI] score >30) through 52 weeks of treatment (8 weeks of induction and 44 weeks of maintenance treatment).1,3 The study included an open-label induction treatment with a single ustekinumab intravenous dose of approximately 6mg/kg followed by a randomized double-blind subcutaneous maintenance regimen of 90mg administered either every 8 weeks or every 12 weeks.

About Ulcerative Colitis
Ulcerative colitis (UC) is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus. It is the result of the immune system's overactive response. Symptoms vary but may typically include loose and more urgent bowel movements, rectal bleeding or bloody stool, persistent diarrhea, abdominal pain, loss of appetite, weight loss, and fatigue.11 

About Crohn's Disease 
Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.12 13 Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.14 Symptoms of Crohn's disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Currently no cure is available for Crohn's disease.15

About TREMFYA® (guselkumab)
Developed by Johnson & Johnson, TREMFYA® is the first fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.

TREMFYA® is a prescription medicine approved in the U.S. to treat:

adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis. adults with moderately to severely active ulcerative colitis. adults with moderately to severely active Crohn's disease.  TREMFYA® is approved in Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate-to-severe Crohn's disease and adults with moderate-to-severe ulcerative colitis.

The legal manufacturer for TREMFYA® is Janssen Biotech, Inc. 

Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA®. For more information, visit: www.tremfya.com.

About Icotrokinra (JNJ-77242113, JNJ-2113)
Investigational icotrokinra is the first targeted oral peptide designed to precisely block the IL-23 receptor16, which underpins the inflammatory response in moderate-to-severe plaque psoriasis, ulcerative colitis and offers potential in other IL-23-mediated diseases.17 18 Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, precise inhibition of IL-23 signaling in human T cells.19 The license and collaboration agreement established between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company, in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to icotrokinra.20 

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson. Johnson & Johnson retains exclusive worldwide rights to develop icotrokinra in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.21 22 23

Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease.

TREMFYA® IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TREMFYA®?

TREMFYA® is a prescription medicine that may cause serious side effects, including:

Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction: o fainting, dizziness, feeling lightheaded (low blood
pressure)

o swelling of your face, eyelids, lips, mouth, tongue
or throat

o trouble breathing or throat tightness

o chest tightness

o skin rash, hives

o itching

Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

o fever, sweats, or chills

o muscle aches

o weight loss

o cough

o warm, red, or painful skin or sores on your body
different from your psoriasis

o diarrhea or stomach pain

o shortness of breath

o blood in your phlegm (mucus)

o burning when you urinate or urinating more often
than normal

Liver problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: o unexplained rash

o vomiting

o tiredness (fatigue)

o yellowing of the skin or the whites of your eyes

o nausea

o stomach pain (abdominal)

o loss of appetite

o dark urine

Do not use TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.

Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:

have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA®?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®. are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing [email protected]. The purpose of this registry is to collect information about the safety of TREMFYA® during pregnancy. are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA®?

TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?"

The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis.

These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.

Use TREMFYA® exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide, for TREMFYA® and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Dosage Forms and Strengths: TREMFYA® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.

WHAT IS STELARA® (ustekinumab)?
STELARA® is a prescription medicine used to treat:

adults and children 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). adults and children 6 years of age and older with active psoriatic arthritis. adults with moderately to severely active Crohn's disease. adults with moderately to severely active ulcerative colitis. IMPORTANT SAFETY INFORMATION
STELARA® is a prescription medicine that affects your immune system. STELARA® can increase your chance of having serious side effects, including:

Serious Infections
STELARA® may lower your ability to fight infections and may increase your risk of infections. Some people have serious infections during treatment with STELARA®, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

Your healthcare provider should check you for TB before starting STELARA® and watch you closely for signs and symptoms of TB during treatment Before starting STELARA®, tell your healthcare provider if you:

think you have an infection or have symptoms of an infection such as: o fever, sweats, or chills
o muscle aches
o cough
o shortness of breath
o blood in phlegm

o weight loss
o warm, red, or painful skin or sores on your body
o diarrhea or stomach pain
o burning when you urinate or urinate more often than normal
o feel very tired

are being treated for an infection or have any open cuts. get a lot of infections or have infections that keep coming back. have TB or have been in close contact with someone with TB. After starting STELARA®, call your healthcare provider right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. STELARA® can make you more likely to get infections or make an infection that you have worse.

People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL-12) and interleukin 23 (IL-23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA® may also be more likely to get these infections.

Cancers
STELARA® may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your healthcare provider if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA®. Tell your healthcare provider if you have any new skin growths.

Serious Allergic Reactions
Serious allergic reactions can occur. Stop using STELARA® and get medical help right away if you get any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.

Posterior Reversible Encephalopathy Syndrome (PRES)
PRES is a rare condition that affects the brain and can cause death. Tell your healthcare provider right away if you get any symptoms of PRES during treatment with STELARA®, including: headache, seizures, confusion, and vision problems.

Lung Inflammation
Cases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your healthcare provider right away if you develop shortness of breath or a cough that doesn't go away during treatment with STELARA®.

Before you use or receive STELARA®, tell your healthcare provider about all of your medical conditions, including if you:

have any of the conditions or symptoms listed above for serious infections or cancers. ever had an allergic reaction to STELARA® or any of its ingredients. Ask your healthcare provider if you are not sure. are allergic to latex. The needle cover on the prefilled syringe contains latex. have recently received or are scheduled to receive an immunization (vaccine). People who are being treated with STELARA® should avoid receiving live vaccines. Tell your healthcare provider if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system and can cause serious problems. You should avoid receiving the BCG vaccine during the one year before receiving STELARA® or one year after you stop receiving STELARA®. have any new or changing lesions within psoriasis areas or on normal skin. are receiving or have received allergy shots, especially for serious allergic reactions. receive or have received phototherapy for your psoriasis. are pregnant or plan to become pregnant. It is not known if STELARA® can harm your unborn baby. You and your healthcare provider should decide if you will receive STELARA®. are breastfeeding or plan to breastfeed. STELARA® can pass into your breast milk. talk to your healthcare provider about the best way to feed your baby if you receive STELARA®. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

When prescribed STELARA®:

Use STELARA® exactly as your healthcare provider tells you to. The healthcare provider will determine the right dose of STELARA®, the amount for each injection, and how often it should be given. Be sure to keep all scheduled follow-up appointments. STELARA® is intended for use under the guidance and supervision of your healthcare provider. In children, it is recommended that STELARA® be administered by a healthcare provider. If your healthcare provider decides that you or a caregiver may give your injections of STELARA® at home, you or a caregiver should receive training on the right way to prepare and inject STELARA®. Do not try to inject STELARA® until you have been shown how to inject STELARA® by a healthcare provider. Common side effects of STELARA® include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, influenza, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with STELARA®. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please read the full Prescribing Information and Medication Guide for STELARA® and discuss any questions you have with your doctor.

ABOUT JOHNSON & JOHNSON 
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.  

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com 

Follow us at @JNJInnovMed. 

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

References:

__________________________

1 Peyrin-Biroulet L, et al. Efficacy and safety of guselkumab for ulcerative colitis through week 140 of the QUASAR long-term extension study. Poster presentation (DOP104) at European Crohn's and Colitis Organisation 2026. February 2026.

2 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn's and Colitis Organization (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504.

3 Kreuger JG, Eyerich K, Kuchroo VK. Il-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024; 15:1331217. doi:10.3389/fimmu.2024.1331217.

4 TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

5 Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie, Inc.

6 Omvoh™ [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.

7 E. Louis, et. al. Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in Ulcerative Colitis: Results from the ANTHEM-UC study. Oral presentation (OP29) at European Crohn's and Colitis Organisation 2026. February 2026

8 D. Turner, et. al.The UNITI Jr Study: Safety and efficacy results of ustekinumab in paediatric patients with Crohn's Disease. Oral presentation (OP18) at European Crohn's and Colitis Organisation 2026. February 2026

9 National Institutes of Health: Clinicaltrials.gov. A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR). Identifier: NCT04033445. https://classic.clinicaltrials.gov/ct2/show/NCT04033445. Accessed February 2026.

10 Clinicaltrials.gov. A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC). Identifier NCT06049017. https://clinicaltrials.gov/study/NCT06049017?term=ANTHEM-UC&rank=1. Accessed February 2026.

11 Crohn's & Colitis Foundation. What is ulcerative colitis? Available at: https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis. Accessed February 2026.

12 Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed February 2026.

13 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.

14 Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed February 2026.

15 Crohn's & Colitis Foundation. Signs and symptoms of Crohn's disease. Available at https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-crohns-disease/symptoms. Accessed February 2026.

16 Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.

17 Razawy W, et al. The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018 Feb; 48(2): 220–229.

18 Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb; 135(2): 112–124.

19 Pinter A, et al. Data Presentation. JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.

20 Johnson & Johnson. Press release. Janssen enters into worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. for the oral Interlukin-23 receptor antagonist drug candidate for the treatment of Inflammatory Bowel Disease. Available at: https://www.jnj.com/media-center/press-releases/janssen-enters-into-worldwide-exclusive-license-and-collaboration-agreement-with-protagonist-therapeutics-inc-for-the-oral-interlukin-23-receptor-antagonist-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease. Accessed February 2026.

21 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html. Accessed February 2026.

22 Protagonist Therapeutics. Press release. Protagonist Reports positive results from Phase 1 and pre-clinical studies of oral Interleukin-23 receptor antagonist JNJ-2113. Available at: https://www.prnewswire.com/news-releases/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html. Accessed February 2026.

23 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces positive topline results for Phase 2b FRONTIER 1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235) in psoriasis. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-topline-results-for-phase-2b-frontier-1-clinical-trial-of-oral-il-23-receptor-antagonist-jnj-2113-pn-235-in-psoriasis-301764181.html. Accessed February 2026.

SOURCE Johnson & Johnson

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

XRP holders, builders and creators hosted a community night event at the ongoing ETHDenver event, one that has attracted the attention of Ripple CEO Brad Garlinghouse on X.

The ETHDenver event marks a Web3 BUIDLathon and Innovation Festival convening over 25,000 builders and creators in the crypto industry, scheduled from Feb. 18 to 21, 2026.

Reacting to an X user's post about the XRP community night Denver gathering, Ripple CEO Brad Garlinghouse tweeted: "love to see it."

HOT Stories

Speaking about the XRP community night Denver gathering, RippleX describes it as a "great evening with the community" while appreciating everyone who joined the event.

Earlier this month, Ripple hosted a successful XRP community day event that convened builders, creators and partners in the XRP Ledger ecosystem.

You Might Also Like

A third stablecoin yield meeting took place at the White House this week with a small group representing crypto and banks attending, with Ripple represented at the event by its chief legal officer, Stuart Alderoty.

Ripple and XRPL newsIn recent news, SBI Ripple Asia has signed a memorandum of understanding (MOU) on a technical support partnership with Asia Web3 Alliance Japan. This partnership will establish a framework in which SBI Ripple Asia will provide technical support to startups and businesses aiming to implement financial services using blockchain technology in society.

The XRP Ledger repository key has been updated ahead of a fix release. According to a recent notice on the XRPL blog, Ripple has rotated the GPG key used to sign rippled packages. Users are urged to download to prevent issues upgrading in the future, as automatic upgrades might not work until they have trusted the new key.

XRP Ledger users should add Ripple's package-signing GPG key and then verify the fingerprint of the newly-added key.

The XRPL Foundation stated that a fix is underway for the batch amendment bug and is undergoing additional validation before being included in a new XRP software update. It is currently preparing a release to formally deprecate the current batch amendments.

XRP sentiment remains cautiously optimistic as Ripple’s strategic partner SBI Holdings unveiled plans to issue $64.5 million in on-chain bonds that reward investors with XRP. While the token has been trading in a narrow range between $1.40 and $1.45, the announcement adds a stronger utility narrative at a time when broader crypto markets are seeking institutional validation.

Rather than relying purely on speculative momentum, XRP’s latest catalyst centers on structured financial products built directly on blockchain infrastructure.

Inside SBI’s On-Chain Bond PlanSBI Holdings confirmed it will launch its first Series ST bonds fully issued, settled, and administered on-chain. The bonds are designed specifically for retail investors and will use digital registration via the ibet for Fin platform developed by BOOSTRY. Trading will occur on the Osaka Digital Exchange’s START system, with secondary trading expected to begin in March 2026.

Interestingly, as per the reward structure, the investors will receive XRP tokens equivalent to their subscription amount after confirmation, provided they meet eligibility requirements. Additional XRP distributions will follow on scheduled interest payment dates through 2029.

By embedding XRP directly into a regulated bond product, SBI is positioning the token within traditional finance structures rather than leaving it solely in the spot trading arena.

Potential Impact for XRPThe potential implications are significant. Some analysts within the XRP community argue that increased demand for the bonds could require consistent XRP purchases to fund subscription rewards and ongoing payouts. If participation grows, this mechanism could generate sustained structural demand for the token.

One X User, Jay Nisbett, linked the initiative to Japan’s yen carry trade dynamic, where investors borrow yen at relatively low rates and allocate capital into higher-yielding assets. In that context, an XRP-linked bond product could channel additional liquidity into instruments tied to the token.

There is also speculation that SBI could scale the $65 million issuance if demand proves strong. Expanding the offering to attract institutional investors would further embed XRP into structured financial products, potentially accelerating institutional adoption beyond simple exchange trading.

While price action remains steady for now, SBI’s bond initiative may serve as a foundational step in expanding XRP’s integration into mainstream financial systems.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

FAQsWhat is SBI Holdings’ XRP on-chain bond plan?

SBI will issue $64.5M in fully on-chain bonds, rewarding eligible retail investors with XRP at subscription and on interest dates through 2029.

Why is SBI’s bond launch important for XRP adoption?

It embeds XRP in a regulated financial product, boosting real-world utility and supporting institutional credibility beyond trading.

Could SBI’s bond issuance increase XRP demand?

Yes. If subscriptions grow, XRP may need to be purchased for rewards and payouts, creating ongoing structural demand.

When will SBI’s XRP-linked bonds begin trading?

Secondary trading is expected to start in March 2026 on the Osaka Digital Exchange’s START system.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Bitcoin, the world’s largest cryptocurrency, has been struggling lately to recover after falling from its all-time high of $126K to around $67K, marking nearly a 50% decline.

While crypto traders eagerly wait for the market to recover, historical data suggest that the Bitcoin price will drop to $40K by no 2026.

Let’s see here’s why!

Why Bitcoin Value Could Fall to $40K?Bitcoin has a history of very deep corrections after reaching new highs. For example, in 2011, BTC value jumped from $1 to $30, only to correct 93% to below $5. In 2015, it fell 85% from $1,100 to $150 after Mt. Gox collapsed. 

In 2018, the Bitcoin price further dipped by 84% from $20K to around $3100 as investors booked profits. 

Similarly, in 2022, BTC fell by 77% from $69K to around $16K after Tesla decided to stop accepting BTC as a payment, which weakened the market confidence.

In this new cycle, Bitcoin already hit a new ATH of $126K in Oct 2025 and is now trading at $67K, down by 50%.

Therefore, if Bitcoin follows its past historical pattern, then BTC will surely dip to 70% from its peak, which will cause the BTC price to reach the $40,000 level.

Market Cycle Predict Bitcoin To Drop To $40K by NovMarket cycle psychology also supports this bearish outlook. Looking at the Wall Street Cheat Sheet, it shows how Bitcoin moves through emotional stages.

Bitcoin reached a high of $126K during the Euphoria stage, when investors were very excited and expected higher prices. Later, Bitcoin entered the stages of Complacency and Anxiety, where prices dropped, but most thought it was only a normal drop to around $97,620 in Jan 2026.

Currently, Bitcoin is entering the Anger and early Depression stage, where fear, frustration, and heavy selling dominate. 

In past cycles, this stage often led to a final bottom, and this time, bitcoin will drop to near $40K, possibly by Nov 2026.

After the bottom forms, Bitcoin usually enters the Disbelief and Recovery stages, where prices slowly rise, and a new bull run begins.

Bitcoin Halving Cycle Could Invalidate Historical TrendMeanwhile, the Bitcoin halving cycle could change this perspective. Because Bitcoin has always peaked after 12 to 18 months after each halving due to a reduction in supply and rising demand. 

After the last BTC halving took place in 2024, Bitcoin may soon enter a strong rally phase by mid-2026, which might invalidate this historical trend.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Uzbekistan has for the first time issued a permit to mine cryptocurrency in its territory, entering the region’s expanding coin minting market.

The move puts an end to months of uncertainty, the newly licensed miner said, promising to “build the infrastructure of the future” in the country.

Uzbekistan greenlights its first legal crypto mining project The Central Asian nation of Uzbekistan has issued its first permit for cryptocurrency mining to a private company, which plans to base its operations in the southwest Bukhara region.

The mining firm, NexaGrid, has received the official authorization from the National Agency of Perspective Projects (NAPP) this week, local media reported late Friday.

The government body, which is directly subordinated to Uzbek President Shavkat Mirziyoyev’s administration, is tasked with enforcing crypto regulations and licensing.

The Tashkent-registered company was established in April 2025, with a statutory capital of 600 million Uzbekistani sums (around $50,000).

In comments quoted by the news outlets Spot and UZ Daily, one of its two founders, Toymurod Sultonov, emphasized that his entity received the permit in a transparent procedure.

In a celebratory post on the professional social network LinkedIn, the former civil servant and textile marketing analyst, turned crypto entrepreneur, also stressed:

“This isn’t just about Bitcoin. It’s about the courage to go where no one has gone before. It’s about months of uncertainty, about the question ‘Why do you need this?’ It’s about risk, pressure, and silence, when no one else believes.”

Private company to pioneer crypto mining in Uzbekistan Sultonov, who has 63% of Uzbekistan’s first licensed mining business, will be managing the enterprise, which will be set up in the Romitan district, with the help of his partner, Makhmudjon Rozimurodov, who owns 37% of its stock.

Commenting further on the positive development, the new crypto executive also noted:

“NexaGrid wasn’t born out of hype — it was born from the idea of building the infrastructure of the future here in Central Asia, where they usually say ‘it’s too early.’”

The move is a significant step for Uzbekistan, which joins Central Asia’s growing crypto mining sector late and needs to catch up with some of its neighbors like Kazakhstan, Kyrgyzstan, and Turkmenistan.

It has been more than two years since the NAPP adopted rules for issuing permits for digital currency mining in the fall of 2023. As per a report by its deputy head, Vyacheslav Pak, there were no legal crypto farms registered in the country in the years that followed.

According to the regulations, legal entities can apply for authorization, provided they have a dedicated mining site that complies with safety standards.

Companies are encouraged to use power generated by their own photovoltaic installations, and when they connect to the public grid, a separate meter must be installed.

Miners are required to thoroughly inform the NAPP about all their activities and file transaction reports. Hidden mining and the minting of anonymous crypto assets are strictly prohibited.

Their license applications must provide detailed information about the solar power plant and any electricity supply agreements, the technical specifications of the mining hardware, including its energy rating, as well as a list of the cryptocurrencies that will be minted and the addresses of the crypto wallets used.

Submission of incomplete data and non-compliance with other relevant regulations may result in rejection of the application if the deficiencies are not corrected within a month after they have been established by Uzbek officials.

Following a 15-day fee-free review process, permits are issued in the form of electronic certificates with QR codes. The licenses are valid for a period of five years, but can be suspended in case of violations for up to six months and even revoked by court order.

Vitalik Buterin laid a foundation for a “cypherpunk-principled, non-ugly Ethereum” that reinforces privacy and censorship resistance, while remaining tightly integrated with the existing network. Buterin highlights FOCIL hardening efforts, including security testing and post-quantum readiness, which are a part of Ethereum’s strengthening plans for 2026. Ethereum’s next chapter is envisioned by Vitalik, which is a ‘cypherpunk upgrade’ and not as a replacement chain, but as a tightly integrated evolution of the existing system.

On February 20, Vitalik Buterin mentioned his ambitious vision for Ethereum in a response to an X post, which said, “Vitalik should let the original ethereum die a slow and painful death by fragmentation (tempo, reth, l2s, app chains, institutions, etc) and rebuild it as a cypherpunk chain from first principles on risc v just to show who was the boss.”

Building on Ethereum, Not a New Chain Buterin had dismissed the idea of abandoning the current Ethereum network due to issues such as fragmentation caused by layer-2 solutions and institutional influence. Rather, he proposed building a “cypherpunk principled non-ugly Ethereum” as a tightly integrated “bolt-on” addition to the existing system.

Which means, he aims to build a simpler version, a more privacy-focused framework that interoperates with today’s Ethereum by adding more features, such as stronger censorship resistance, zero-knowledge proof compatibility, and simpler consensus.

Buterin also said that this newly set system can allow smart contracts to be rewritten in a more elegant, verifiable language, using AI tools, that potentially reshapes how developers and users interact with Ethereum in the next five years.

Further, Buterin echoed the confidence by saying, “Ethereum has already made jet engine changes in-flight once (the merge), we can do it ~4 times more!”

Strengthening Ethereum for 2026 Previously, the Ethereum Foundation released its protocol priorities for the year 2026, in which they mentioned there are three new tracks to be focussed such as scaling, improving UX, and hardening the chain. With that, on Thursday, Buterin wrote about Fork-Choice Enforced Inclusion Lists (FOCIL) as a major step toward strengthening Ethereum.

Also, on Friday, Buterin wrote that the 2026 upgrade includes network security testing, post-quantum readiness, and mentioned. “Ethereum will emerge from the year a far stronger, more powerful, and more self-sovereign protocol than what it was entering this year.”

Highlighted Crypto News:

Bitcoin Below $70K: Ecoinometrics Warns of Further Downside

Journalist

Posted: February 21, 2026

Polygon [POL] continued to trade within a thin margin, still holding the $0.10 support level. The altcoin flipped its short-term moving average EMA20, signaling strengthening momentum. 

At the time of writing, POL traded at $0.108, up 4.06% on the daily charts. This slight price uptick was backed by a 17% jump in trading volume, indicating increased on-chain activity. 

Polygon burns 100M tokens With POL struggling to hold an upside momentum, Polygon has continued to deploy its major deflationary tool to absorb market pressure.

According to the official report, Polygon has achieved a major milestone, burning 100 million POL. Typically, token burns help shrink the circulating supply, reduce inflation, and thus accelerate an asset’s upside momentum. 

Even more importantly, sustained token burns reflect higher fees and network revenue, a sign of increased network usage and adoption.

Source: Defillama

In fact, at the time of writing, Daily Fees and Revenue have stabilized above $200k, with App Fees holding above $500k. When network revenue continues to rise, it suggests higher network participation and actual demand. 

A network with sustained demand can boost its native token, potentially driving prices higher. 

Any impact on POL price action? In the short term, Polygon’s token burns have tended to positively impact POL’s price, as the altcoin slightly jumped from the lower boundary.

Notably, the altcoin’s Stochastic RSI made a bullish crossover and rose to 88.27 as of writing, although its signal line remained around 88.

Source: TradingView

With Stoch rising to such levels, it suggested strong upside momentum as demand stepped into the market. However, the signal remained roughly the same, suggesting a strong seller presence.

Such market conditions indicate a fierce struggle between bulls and bears for market control. For a bullish takeover, POL buyers must push for a daily close above the EMA 20 and EMA 50 at $0.11, setting up a move towards $0.12.

However, if the momentum turns short-lived and sellers cash out these minor gains, the altcoin will pull back towards $0.106.

Inflo remains elevated Interestingly, despite continued token burns, POL’s inflation remains extremely elevated, signaling higher sell pressure. According to Santiment data, the altcoin’s Stock-to-Flow Ratio continued to decline, falling to 8.6 at press time. 

Source: Santiment

A drop in SFR suggests low scarcity and increased immediate supply. A high supply presents a significant selling pressure in the market. 

Even more so, the altcoin’s Exchange Supply Ratio surged to a monthly high of 0.003. When ESR rises, it suggests that a significant amount of Polygon has recently flowed into exchanges. 

Source: CryptoQuant

Therefore, sellers are more active than buyers on exchanges, further straining the already overwhelmed market. Typically, such market conditions tend to accelerate downside momentum, leading to lower prices.

Final Summary Polygon reaches a major deflationary milestone by burning 100 million POL tokens, though inflation remains elevated.  POL rose 4% on daily charts, flipping EMA20, indicating short-term bullish momentum.

Is ETH finally going to rebound decisively, or will there be another crash to new lows.

Ethereum continues to struggle to reclaim the coveted $2,000 psychological level, as each attempt to do so results in a subsequent rejection and correction.

Popular analyst Ali Martinez weighed in on the asset’s recent performance and explained that it’s forming a bullish flag. However, there’s a major catch in his post, which could actually mean trouble ahead for ETH.

Ethereum $ETH is forming a bullish flag!

There’s just one twist… The chart is inverted. pic.twitter.com/Kb8eamJOMF

— Ali Charts (@alicharts) February 20, 2026

The “inverted” bullish flag shows that ETH has actually been in a consistent downtrend for weeks, but it has managed to compress within a tighter range more recently. Martinez believes a bigger move is in the making, but it could push the asset to new local lows of under $1,400.

Daan Crypto Trades also brought up ETH’s underwhelming performance as of late, indicating that the start of 2026 has been worse than how it moved in early 2025.

The analyst outlined hopes that the largest altcoin could finally rebound in the following few months, since the March-to-May period is historically more beneficial for it.

$ETH Has started the year of worse than last year so far. Historically, March through May are good months for ETH.

But we know how the market is all over the place recently and that there’s been pretty much zero correlation with other risk assets.

This makes for an awful… pic.twitter.com/CBAfLTduHx

— Daan Crypto Trades (@DaanCrypto) February 21, 2026

You may also like: Peter Thiel Exits ETHZilla, Company Sells $74.5M in ETH Amid Market Pressure Ethereum Is Neutral, People Aren’t: Vitalik Buterin Draws a Clear Line Tom Lee Says Ethereum Has Never Failed This Pattern and Expects Another V-Shaped Recovery Another unfavorable development within the Ethereum investor ecosystem is the net flows within the spot ETH ETFs. Last week was in the red once again, with roughly $113 million leaving the funds.

On the opposite side, BitMine continues to accumulate. The Tom Lee-chaired company bought another 45,759 ETH last week, and now holds 4,371,497 tokens, valued at almost $8.7 billion. The company is down $8 billion on its Ethereum position, given its average entry cost of $3,820.

Tags:

About the author

Jordan got into crypto in 2016 by trading and investing. He began writing about blockchain technology in 2017 and now serves as CryptoPotato's Assistant Editor-in-Chief. He has managed numerous crypto-related projects and is passionate about all things blockchain.

Top bluechip crypto assets are heading into the weekend flashing something traders rarely ignore these are negative 30-day MVRV readings. Ethereum sits at -14.3%, while Bitcoin follows at -6.9%, with Chainlink (-5.1%), XRP (-4.1%), and Cardano (-2.0%) close behind. 

In simple? Average trader returns are below zero. That doesn’t guarantee a bounce. But it does change the risk calculus.

MVRV Says “Discount” in Top Bluechip Crypto AssetsSantiment’s 30-day MVRV isn’t hype-driven. It simply measures average returns over the last month and signals when assets drift into undervalued or overvalued territory. And right now, the message is blunt, as onchain chart shows large caps are sitting below their usual neutral zone.

Ethereum is the most discounted of the group. That -14.3% figure implies short-term holders are deep enough underwater to historically tilt conditions toward relief moves. 

Meanwhile, Bitcoin’s -6.9% suggests milder pressure, but still below equilibrium. LINK/USD, XRP/USD, and ADA/USD are also slightly negative but not extreme, yet far from overheated.

Well, undervalued doesn’t automatically mean instant rally. But, it means positioning risk skews differently.

Momentum Still BTC & ETH-LedTechnically speaking, correlation remains obvious. The Bitcoin price chart and ETH/USD structure continue to dictate broader bluechip behavior, even in 2026. 

Also, XRP price prediction chatter on social platforms like X, and Cardano price prediction threads, and even Chainlink price prediction setups all are discusssed in correlation to first born crypto’s even today. Even on price action these tend to shadow whatever direction BTC/USD and ETH/USD establish first.

Despite distinct fundamentals and ecosystems, these five assets are moving in similar momentum waves. When the first movers consolidate, the rest pause. When they expand, liquidity rotates outward.

So yes, there’s slight divergence in absolute price levels. But trend timing? Strikingly aligned.

Relief Rally Levels to WatchShort-term projections put potential relief levels around $98,737 for BTC/USD, $3,474 for ETH/USD, $2.37 for XRP/USD, $0.49 for ADA/USD, and $14.84 for LINK/USD. These aren’t moon targets but they’re structural resistance markers.

If reclaimed and consolidated above, long-term sentiment would flip more constructive. But, if rejected, the reset phase extends and lower lows remain possible in all top 5.

And that’s the uncomfortable part. Because while MVRV says “discount,” price structure says “prove it.”

Additionally, the Accumulation-style consolidation has been visible across the board in 2026. But Top bluechip crypto trends won’t sustainably pivot unless leadership breaks decisively. Until then, undervalued readings reflect opportunity and risk in equal measure.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Plutus, the native smart contract language for Cardano, has welcomed a new release as the network prepares for its intra-era hard fork.

According to Cardano updates, an X handle dedicated to Cardano releases and updates, a new version of Plutus, 1.58.0.0, has been released.

This follows efforts by Cardano's core technology teams to expand Plutus built-in functionality scheduled for activation in protocol version 11 alongside stability improvements across networking and mempool handling.

HOT Stories

Cardano's next protocol upgrade is an intra-era hard fork to protocol version 11, introducing targeted improvements across Plutus performance, ledger consistency and node-level security. All these will occur without changing transaction shape or transitioning to a new ledger era.

You Might Also Like

This week, node v.10.6.2 was released in preparation for the intra-era hard fork. Additionally, foundational work was added to support the upcoming intra-era hard fork (protocol version 11) and the future Dijkstra era (protocol version 12), preparing the node for the next phase of protocol evolution.

Cardano hard fork updateCardano's intra-era hard fork to protocol 11 has been officially confirmed as van Rossem hard fork, Intersect stated this in a Feb. 19 update.

Over the past week, the hard fork naming info action ended voting with final tallies putting the DRep support at over 80% of all active DRep stake. This represents overwhelming support, officially confirming the protocol version 11 hard fork as the van Rossem hard fork.

Cardano node version 10.6.2 was released this week (promoted from the 10.6.2 pre-release containing hard fork functionality, which can be tested on SanchoNet). This release contains improvements that strengthen node stability and networking.

The 10.6.2 release is not intended to be the mainnet hard fork candidate release; 10.7 will have further improvements, making it the target for the hard fork.

SanchoNet has been upgraded using the newly-released Cardano node 10.6.2 and is now running protocol version 11. There is also an accompanying DB-Sync pre-release available, which supports hard forking to protocol version 11.

The Cardano node 10.7.0 release is targeted for within the next two weeks. This node release will be used for fork preview, preprod and then the Cardano mainnet.

As the crypto industry adopts AI-focused blockchain netowrk it is exposing itself to more security risks. IoTeX, a blockchain platform built for real-world AI, recently suffered a major security hack, resulting in nearly $8 million in losses.

Here’s how the hack happened & how the IoTeX team is responding to it. Are users’ funds safe?

How The IoTeX Hack Happened?PeckShield, a blockchain security firm, said the hacker carried out the attack after compromising a private key. As a result, the hacker had complete access to the token safe and could take out various cryptocurrency assets.

The hacker compromised several tokens, including USDC, USDT, IOTX, PAYG, WBTC, and BUSD. They withdrew these assets directly from the smart contract vault, showing they had authorized access rather than exploiting a smart contract bug.

The attack turned serious when the hacker allegedly used the same access to create 111 million CIOTEX tokens.

This unauthorized token creation increased the scale of the damage and raised concerns about token supply integrity.

Stolen Funds Converted From ETH to BitcoinThe hacker quickly began the process of transferring the stolen assets after stealing the money.

Later, the hacker traded the stolen tokens for Ethereum. The hacker then used the THORChain cross-chain protocol to bridge Ethereum to Bitcoin.

This step makes tracking and recovery more difficult, as funds move across different blockchain networks and become harder to freeze.

Following the hack, the IoTeX native token IOTX drop 7%, trading below $0.050 with a market cap hitting $47.46 million.

IoTeX Team Responds With Investigation In reaction to the hack, IoTeX was quick to post on X confirming that they were aware of the hack and were working to investigate the issue.

The team confirmed that they were working with major crypto exchanges and blockchain security partners to trace back the stolen funds and stop any further movement.

We are aware of recent reports regarding suspicious activity involving an IoTeX token safe. Our team is fully engaged, working around the clock to assess and contain the situation.

Initial estimates indicate the potential loss is significantly lower than circulating rumors…

— IoTeX (@iotex_io) February 21, 2026 At the same time, exchanges and partners are helping monitor wallets linked to the attacker and may freeze assets if they enter centralized platforms.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

IoTeX’s cross-chain bridge was hit by a private key exploit on February 21, draining over $8 million in crypto assets and sending the IOTX token tumbling. The attack, which unfolded between 7 and 9 AM UTC, gave the hacker control over IoTeX’s TokenSafe and MinterPool contracts.

On-chain analyst Specter was among the first to flag the breach, reporting that the attacker drained $4.3 million in tokens including USDC, USDT, IOTX, PAYG, WBTC, and BUSD. The stolen assets were quickly swapped to ETH, with approximately 45 ETH bridged to the Bitcoin network.

But that was only part of the damage.

Attacker Minted Millions in CIOTX and CCS TokensBeyond the initial drain, the hacker exploited the compromised contracts to mint $4 million in CIOTX tokens and $4.5 million in CCS, pushing total estimated losses toward $9 million.

Blockchain security firm PeckShield confirmed the exploit on X, writing: “The IoTeX Bridge has been hacked for over $8M worth of crypto due to a compromised private key. The hacker has swapped the stolen funds to $ETH and has started bridging them to BTC via THORChain.”

Three attacker addresses have been publicly identified so far.

IoTeX Says Actual Losses Are LowerIoTeX confirmed the breach by 10:30 AM UTC and pushed back on the circulating estimates. The team stated that “initial estimates indicate the potential loss is significantly lower than circulating rumors suggest.”

The company added that it has “already coordinated with major exchanges and security partners, which are actively assisting in tracing and freezing the hacker’s assets.”

We are aware of recent reports regarding suspicious activity involving an IoTeX token safe. Our team is fully engaged, working around the clock to assess and contain the situation.

Initial estimates indicate the potential loss is significantly lower than circulating rumors…

— IoTeX (@iotex_io) February 21, 2026 IOTX Price Reacts to the ExploitIOTX is currently trading near $0.0049, down 9.2% over the last 24 hours, with daily volume surging over 507%.

This incident follows a rough stretch for cross-chain bridges in 2026. Just three weeks ago, CrossCurve lost $3 million in a separate bridge exploit, and January alone saw nearly $400 million in total crypto thefts industry-wide.

IoTeX says the situation is “under control” and has promised continued updates. Analysts are now watching whether the frozen funds can be recovered before the attacker moves them further.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

A seasoned investor’s bold claim about XRP has reignited a common question in crypto markets: could a token built for fast settlement ever outgrow the original store-of-value?

According to posts on X by longtime Bitcoin backer Pumpius, if central banks adopt a single on-chain bridge, XRP could eclipse Bitcoin “by magnitude.”

On-Chain Tension And Policy Moves Reports note recent market moves that have worried policy makers and traders. The trading desk at the Federal Reserve requested indicative dollar/yen quotes after a sharp move in the yen, a step that Treasury officials had asked for.

That rare check underlines how currency volatility can push officials to consider new tools, and it has renewed talk about faster settlement rails.

Every Central Bank will use XRP as the bridge asset.

It’s now becoming a reality.

When this happens, XRP will surpass Bitcoin by magnitude.

Bookmark this. https://t.co/xyWxhVDCLx pic.twitter.com/kFTsXSw6Hn

— Pumpius (@pumpius) February 19, 2026

Ripple’s Timeline And Institutional Talk Based on reports from company briefings and executive posts, Ripple’s leadership sees 2026 as the year when larger, regulated players might put real money onto the XRP Ledger.

Ripple President Monica Long has sketched out scenarios where banks and asset managers run production systems tied to on-chain liquidity pools. Those views have been picked up across crypto news outlets and have added fuel to bullish narratives.

How Would A Bridge Asset Work? Imagine dollar and euro liquidity on a ledger, available for near-instant swaps. In practice, permissioned pools and regulated stablecoins could provide the rails while an on-chain order book or matching engine handles the trades.

Settlement times would be measured in seconds. Audit trails would be automatic. That said, large institutions put a premium on rules and oversight; any real rollout would be gradual and cautious.

XRPUSD currently trading at $1.44. Chart: TradingView XRP Vs. BTC: The Size Of The Gap Numbers matter. Bitcoin’s market cap sits comfortably in the trillions, while XRP’s market value is under $100 billion dollars, depending on which tracker you consult.

That gap is not small. For XRP to “flip” Bitcoin at present values would require trillions more in capital moving into the token — a shift that would likely need broad institutional flows and major regulatory clarity.

Geopolitics Adds Noise Geopolitical strain and trade frictions, amplified by speeches or decisions from leaders, can make markets jittery. US President Donald Trump has been named in debates over policy shifts and geopolitical risk, which in turn affect capital flows and safe-haven bids.

When politics moves markets, technical fixes such as faster settlement can look more attractive on paper; adoption in practice is another matter.

Featured image from Unsplash, chart from TradingView

TL;DR Bitcoin and gold reflect opposing expectations about US economic policy under Donald Trump, with investors using both assets as macro signals. Gold demand has increased alongside rising fiscal deficits and debt concerns, while Bitcoin trades as a bet on deregulation and pro-crypto reforms.

These REITs stand out in the crowded sector.

The real estate investment trust (REIT) sector is massive. According to the National Association of REITs (Nareit), there are currently 191 publicly traded REITs. They have a combined market capitalization approaching $1.5 trillion.

Given the sector's size, it's impossible to know about every REIT. Instead, investors should focus on the best the industry has to offer. Here are three REITs that every investor should know about.

Image source: Getty Images.

Federal Realty Investment Trust Federal Realty Investment Trust (FRT +1.51%) stands out in the REIT sector for doing one thing exceptionally well. It has increased its dividend for an industry-leading 58 straight years. That qualifies it as a Dividend King, a company with at least 50 years of consecutive annual dividend increases. It's the only REIT that has reached Dividend King status.

The company focuses on investing in quality over quantity. It owns 104 high-quality open-air retail and mixed-use properties in the top suburban markets densely populated with high-income households. Despite being in business for more than six decades, Federal Realty has a much smaller portfolio than other retail REITs (e.g., Kimco owns 565 shopping centers and mixed-use assets).

Today's Change

(

1.51

%) $

1.60

Current Price

$

107.47

Federal Realty routinely upgrades its portfolio. It sells mature properties with lower rent growth upside to recycle capital into new properties with greater growth potential, and to fund redevelopment and expansion projects at its other properties. For example, it has sold $328 million of properties over the past few months, which helped fund the $340 million it spent on two new properties. It also announced plans to invest up to $120 million in the redevelopment of another property. This strategy of investing in quality over quantity should enable Federal Realty to continue increasing its dividend.

Realty Income Realty Income (O +0.92%) is the world's sixth-largest REIT with over $61 billion in real estate across nine countries. It's a global leader in net-lease real estate (properties secured by long-term triple-net leases, under which tenants cover all property operating costs). The landlord has a diversified portfolio consisting of over 15,500 retail, industrial, gaming, data center, and other properties leased to many of the world's leading companies, including FedEx, Walmart, and Home Depot.

Today's Change

(

0.92

%) $

0.60

Current Price

$

66.10

Net-leased properties provide very stable rental income. That enables Realty Income to pay a dependable monthly dividend. The REIT steadily increases its dividend. It has raised its payment for more than 30 straight years, including the past 113 quarters in a row.

New investments are the primary driver of the REIT's growing dividend. Realty Income spends billions of dollars each year to acquire stabilized properties and invest in build-to-suit development projects. It sees a massive $14 trillion opportunity to invest in net lease real estate across the U.S. and Europe.

Prologis Prologis (PLD +1.78%) is one of the world's largest REITs. It owns interests in nearly 5,900 buildings in 20 countries. The REIT has over $215 billion in assets under management, including properties it owns outright and those held in investment funds it manages.

Today's Change

(

1.78

%) $

2.47

Current Price

$

141.51

Prologis primarily invests in warehouses. These logistics properties are vital to supporting the global economy. A staggering $3.2 trillion in goods flows through its distribution centers each year, representing 2.9% of global GDP.

The REIT has also begun investing in data centers to support the massive $7 trillion in investment needed for this digital infrastructure. Prologis estimates it could invest between $30 billion and $50 billion in developing data centers over the next decade, creating up to $25 billion in value for its investors.

The company's investments to grow its portfolio should enable it to continue increasing its dividend. Prologis has grown its payout at a 13% compound annual rate over the last five years, more than double the REIT sector's average of 6%.

These top REITs deliver durable and growing dividends Federal Realty Investment Trust, Realty Income, and Prologis are three of the top REITs. They have long histories of growing shareholder value, including steadily increasing their dividends. That makes them ideal REITs to buy and hold long-term.

Matt DiLallo has positions in FedEx, Home Depot, Prologis, and Realty Income. The Motley Fool has positions in and recommends Home Depot, Prologis, Realty Income, and Walmart. The Motley Fool recommends FedEx. The Motley Fool has a disclosure policy.

Vita Coco's Stock Is Still Too Expensive After The Pullback

If the artificial intelligence (AI) buildout plays out the way bulls expect, Oracle (ORCL 5.40%) is positioned to win big.

Oracle is all in on AI Oracle Cloud Infrastructure (OCI) revenue is growing 66% year over year (YOY), and its backlog has exploded to over $523 billion on the back of massive AI contracts with Meta Platforms, Nvidia, and OpenAI. OCI is now the fastest-growing major cloud platform, beating Amazon Web Services and Microsoft's Azure.

Today's Change

(

-5.40

%) $

-8.46

Current Price

$

148.08

Oracle needs a lot to go just right The problem is that the company is betting the farm, so to speak. It's taking on tens of billions in debt and considering the sale of profitable business units to fund the data center buildout needed to serve its AI customers and collect on that massive backlog.

If all goes well, the bet will pay handsomely and leave Oracle as a dominant player in the industry. If it doesn't, the company could be in dire straits financially, and the stock would be in the proverbial tank.

Image source: Getty Images.

The verdict If you ask me, there's plenty of reason to believe that it won't play out how the bulls hope. The vast majority of that backlog is supposed to come from OpenAI, a company with financial commitments that absolutely dwarf even its top-line revenue, let alone its net income, which happens to be deeply negative.

That's not a risk-reward profile I like. Oracle is not a stock I would own at this point.

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Meta Platforms, Microsoft, Nvidia, and Oracle. The Motley Fool has a disclosure policy.

Vishay Precision: AI Opportunity Keeping The Story Alive, But I'm Remaining Skeptical

Commerce is becoming fragmented, and prices on the basic building blocks of the economy are more volatile.

U.S.-Iran Nuclear Standoff Remains the Primary Driver of the Rally In my opinion, the primary driver of the rally was the U.S.-Iran nuclear standoff. It had been underpinning prices most of the week. With the U.S. sending another warship fleet and giving Iran a 10-to-15-day advanced warning of attack, the situation escalated, reinforcing gold as a safe-haven asset.

Supreme Court Tariff Ruling Knocks the Dollar, Sending Gold Higher The second most influential factor was the U.S. Supreme Court ruling that struck down President Trump’s broad tariff powers. The news drove down the U.S. Dollar, which had been edging higher at the time, making gold more attractive to foreign buyers. Later in the trading session, prices rose further as traders reacted to Trump’s announcement of fresh global tariffs.

The Supreme Court first declared illegal Trump’s use of the International Emergency Economic Powers Act to impose global tariffs. He then said he would impose a 10% global tariff for 150 days to replace some of his emergency duties that the Court struck down. Both moves were read as bullish by traders.

Weak GDP and Sticky PCE Trim June Rate Cut Odds but Fail to Derail the Rally Gold traders showed little reaction to mixed U.S. economic news that dampened the chances of a Fed rate cut in June. U.S. GDP was weaker than expected and PCE inflation came in as expected but still above the 2% mandate. According to the CME FedWatch Tool, this drove the chances of a June rate cut lower from 50.2% on Thursday to 45.6% at Friday’s close.

The economic data drove the dollar higher, so gold’s gains may have been limited at the time, but the dollar turned lower and gold gained further once the tariff news came out at around 14:30 GMT.

Technical Outlook: $5108 High Puts Gold Just Under Key Resistance at $5119 and $5143

indie Semiconductor: Still Waiting On Inflection